1. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
- Author
-
Liang BB, Wang YH, Huang JJ, Lin S, Mao GC, Zhou ZJ, Yan WJ, Shan CY, Wu HZ, Etcheverry A, He YL, Liu FF, Kang HF, Yin AA, and Zhang SQ
- Subjects
- Humans, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, DNA Modification Methylases drug effects, DNA Modification Methylases genetics, DNA Repair Enzymes drug effects, DNA Repair Enzymes genetics, Phenotype, Tumor Suppressor Proteins genetics, Receptors, G-Protein-Coupled drug effects, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms radiotherapy, DNA Methylation drug effects, Glioblastoma drug therapy, Glioblastoma genetics, Glioma drug therapy, Glioma genetics, Temozolomide pharmacology, Temozolomide therapeutic use
- Abstract
Purposes: To identify potent DNA methylation candidates that could predict response to temozolomide (TMZ) in glioblastomas (GBMs) that do not have glioma-CpGs island methylator phenotype (G-CIMP) but have an unmethylated promoter of O-6-methylguanine-DNA methyltransferase (unMGMT)., Methods: The discovery-validation approach was planned incorporating a series of G-CIMP-/unMGMT GBM cohorts with DNA methylation microarray data and clinical information, to construct multi-CpG prediction models. Different bioinformatic and experimental analyses were performed for biological exploration., Results: By analyzing discovery sets with radiotherapy (RT) plus TMZ versus RT alone, we identified a panel of 64 TMZ efficacy-related CpGs, from which a 10-CpG risk signature was further constructed. Both the 64-CpG panel and the 10-CpG risk signature were validated showing significant correlations with overall survival of G-CIMP-/unMGMT GBMs when treated with RT/TMZ, rather than RT alone. The 10-CpG risk signature was further observed for aiding TMZ choice by distinguishing differential outcomes to RT/TMZ versus RT within each risk subgroup. Functional studies on GPR81, the gene harboring one of the 10 CpGs, indicated its distinct impacts on TMZ resistance in GBM cells, which may be dependent on the status of MGMT expression., Conclusions: The 64 TMZ efficacy-related CpGs and in particular the 10-CpG risk signature may serve as promising predictive biomarker candidates for guiding optimal usage of TMZ in G-CIMP-/unMGMT GBMs., (© 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF